Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBunzl Regulatory News (BNZL)

Share Price Information for Bunzl (BNZL)

Share Price is delayed by 15 minutes
Get Live Data
2,390.00    108.00 (4.73%)
Bid:
2,380.00
Ask:
2,384.00
Spread: 4.00 (0.168%)
Market Cap: £7.67b
BNZL Live PriceLast checked at - London Stock Exchange

Intraday Bunzl Share Chart

Trading Statement

26 Oct 2021 07:00

RNS Number : 1860Q
Bunzl PLC
26 October 2021
 

26 October 2021

BUNZL Q3 TRADING STATEMENT

 

Bunzl plc, the specialist international distribution and services Group, today announces its trading statement for the period since 30 June 2021.

 

Bunzl's diversified and resilient business model has delivered strong overall growth against a background of continuing pandemic-related challenges. Group revenue for the third quarter was 7.8% higher year-on-year at actual exchange rates, an increase of 13.0% at constant exchange rates. Acquisitions contributed revenue growth of 4.3% at constant exchange rates, while a greater number of trading days than the comparable period in 2020 further benefited revenue growth by 6.2% although this will unwind in the fourth quarter. Underlying revenue growth at constant exchange rates was 2.5%. Group adjusted operating margin was, as expected, impacted by ongoing deflation in certain Covid-19 related products.

 

Within underlying revenue growth of 2.5%, the strong recovery in the base business contributed underlying sales growth of 12.0%, with broad strength across business areas and continued support of product inflation particularly in North America. This growth was largely offset by a 9.4% impact on underlying growth from a decline in sales of top 8 Covid-19 related products, which are primarily own brand. Underlying revenue for the third quarter was approximately 10% higher than the comparable 2019 period.

 

With good revenue performance year to date the Group now expects slight underlying revenue growth in 2021 compared to 2020 at constant exchange rates. Given the strength of performance in 2020 revenue is expected to demonstrate good underlying growth compared to 2019, highlighting the quality and resilience of the Bunzl business model. Margin expectations for the year are unchanged, with adjusted operating margin expected to be only slightly ahead of historical levels. With 2021 continuing to reflect pandemic-related dynamics, we continue to expect to see a further normalisation of Group operating margin in 2022 to more historical levels, as the mix of sector and product sales returns to more typical levels for the Group.

 

The Group also announces today that at the end of September it completed the acquisition of Intergro LLC ("Intergro"), a distributor of agricultural supplies to commercial growers in the Eastern US with a strong own brand portfolio. Intergro generated revenue of £17 million in 2020 and is complementary to our existing agriculture business in North America. The Group also completed the previously announced acquisition of McCue Corporation during October following competition clearance.

 

Frank van Zanten, Chief Executive Officer of Bunzl, commented:

 

"At our recent Capital Markets Day, as well as providing insights into the opportunity that sustainability presents to Bunzl, we highlighted the strength of our compounding strategy which has delivered strong shareholder returns for many years. This track record of success continues with another good trading performance in Q3 and the acquisition of Intergro, which is our 11th acquisition year to date. Intergro is complementary to our existing agricultural business and broadens the Group's product offering to customers. Our acquisition pipeline remains active, supported by the strength of our balance sheet."

 

 

Enquiries:

Bunzl plc

Frank van Zanten, Chief Executive Officer

Richard Howes, Chief Financial Officer

Sunita Entwisle, Head of Investor Relations

Tel: +44 (0)20 7725 5000

Tulchan

Martin Robinson

Olivia Peters

Tel: +44 (0)20 7353 4200

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBUBDGLSDDGBU
Date   Source Headline
3rd Jan 202311:43 amRNSTotal Voting Rights
21st Dec 20227:00 amRNSTrading Statement
20th Dec 20227:00 amRNSAcquisition
14th Dec 20228:00 amRNSAdditional Listing
8th Dec 202212:56 pmRNSHolding(s) in Company
5th Dec 20229:45 amRNSDirector/PDMR Shareholding
1st Dec 20222:34 pmRNSTotal Voting Rights
29th Nov 20223:21 pmRNSDirector/PDMR Shareholding
11th Nov 20229:00 amRNSPublication of Admission Particulars
4th Nov 202212:08 pmRNSDirector/PDMR Shareholding
2nd Nov 20224:20 pmRNSDirector/PDMR Shareholding
1st Nov 20223:00 pmRNSTotal Voting Rights
1st Nov 202210:00 amRNSBlock listing Interim Review
20th Oct 20227:00 amRNSTrading Statement
11th Oct 20227:00 amRNSInvestor event
7th Oct 20224:11 pmRNSDirector/PDMR Shareholding
4th Oct 20224:54 pmRNSDirector/PDMR Shareholding
3rd Oct 20223:13 pmRNSTotal Voting Rights
20th Sep 20227:00 amRNSHolding(s) in Company
7th Sep 202210:59 amRNSDirector/PDMR Shareholding
1st Sep 202211:08 amRNSTotal Voting Rights
31st Aug 20221:46 pmRNSDirector/PDMR Shareholding
30th Aug 202210:00 amRNSDividend Declaration
30th Aug 20227:00 amRNSHalf-year Report
4th Aug 20229:19 amRNSDirector/PDMR Shareholding
2nd Aug 20227:00 amRNSAcquisition
1st Aug 20223:07 pmRNSTotal Voting Rights
1st Aug 202210:00 amRNSDirector Declaration
29th Jul 20227:00 amRNSAppointment of Joint Corporate Broker
19th Jul 20227:00 amRNSDirectorate Change
12th Jul 202210:32 amRNSDirector/PDMR Shareholding
6th Jul 20225:12 pmRNSDirector/PDMR Shareholding
1st Jul 20222:18 pmRNSTotal Voting Rights
30th Jun 20227:00 amRNSTrading Statement
14th Jun 20227:00 amRNSAcquisition
8th Jun 202212:44 pmRNSDirector/PDMR Shareholding
1st Jun 202210:42 amRNSTotal Voting Rights
11th May 20228:00 amRNSAdditional Listing
5th May 202211:00 amRNSDirector/PDMR Shareholding
3rd May 202211:00 amRNSTotal Voting Rights
3rd May 202210:00 amRNSBlock listing Interim Review
28th Apr 20228:00 amRNSAdditional Listing
20th Apr 20225:17 pmRNSResult of AGM
20th Apr 20227:00 amRNSTrading Statement
19th Apr 20224:59 pmRNSDirector/PDMR Shareholding
8th Apr 20225:37 pmRNSDirector/PDMR Shareholding
8th Apr 20225:36 pmRNSDirector/PDMR Shareholding
7th Apr 20222:45 pmRNSDirector/PDMR Shareholding
5th Apr 20224:03 pmRNSDirector/PDMR Shareholding
1st Apr 20223:52 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.